Form 4: Shelly Wong Sells ALX Oncology Shares

Shelly Wong, SVP, Finance and CAO of ALX Oncology Holdings Inc., reported a sale of 1,404 common shares on July 1, 2026, to cover tax obligations related to vesting restricted stock units.

Summary

• Shelly Wong, SVP, Finance and CAO of ALX Oncology Holdings Inc., sold 1,404 shares of common stock on July 1, 2026.
• The sale was executed at a weighted average price of $2.04 per share, with individual transactions ranging from $2.02 to $2.04.
• The shares were sold to satisfy the reporting person's tax obligations arising from the vesting of restricted stock units.
• Following the transaction, Shelly Wong beneficially owns 88,401 shares.
• This transaction was made pursuant to a Rule 10b5-1(c) trading plan.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider sale, though the clear explanation of tax obligations and the use of a 10b5-1 plan mitigate significant concern.

Negatives

• Sale of company stock by a key executive, which could be perceived negatively by the market.
• The sale was to cover tax obligations, indicating a need for liquidity from the executive.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling, particularly by senior finance executives, can sometimes be interpreted as a signal of reduced confidence, although in this case, the sale is explicitly tied to tax obligations from vesting RSUs and executed under a 10b5-1 plan, which are standard procedures.

Stakeholder Impact

• Shareholders: May view the sale by a senior executive with some concern, although the stated reason (tax obligations) and the use of a 10b5-1 plan are mitigating factors.

Key Dates

Keywords

ALX Oncology Holdings Inc., ALXO, Form 4, Insider Trading, Stock Sale, Shelly Wong, Restricted Stock Units, Tax Obligations, Rule 10b5-1(c)